Immuno-therapy (ITH)

Christopher Rudd, Chair
Department of Pathology
University of Cambridge
Tennis Court Road
Cambridge, UK CB2 1QP

Lisa Butterfield
University of Pittsburgh Research Pavilion,
Hillman Cancer Center
5117 Centre Avenue Pittsburgh, PA 15213

Olivier Boyer
Inserm U905 Pathophysiology and biotherapy
of inflammatory and autoimmune diseases
Rouen University
22, bd Gambetta
76000 Rouen
France

Jiřina Bartůňková
Institute of Immunology,
Charles University and University Hospital
Motol V Úvalu 84 150 06
Praha 5 Czech Republic

Winfried F. PICKL
Institute of Immunology
Medical University of Vienna
Borschkegasse 8a
1090 Vienna, Austria

David Rothstein
Thomas E Starzl Transplant Institute
University of Pittsburgh
200 Lothrop Street W1545
Biomedical Science Tower
Pittsburgh, PA 15261

Bo Huang
National Laboratory of Medical Molecular Biology
Department of immunology
Institute of Basic Medical Sciences
Chinese Academy of Medical Sciences
5 Dong Dan San Tiao
Beijing 100005
ITH Mandate

• To develop awareness of international immunotherapy
• Develop policy positions on the use and application of immunotherapy
• Liaise with other international groups with an interest in immunotherapy
• Develop standards and protocols in the application of immunotherapies
• Explore low cost alternatives to present therapies for the developing world
ITH Committee Activities

• Relatively low level. No money yet available; money allocated for this year.

• Begun to write an article for Frontiers in Immunology, and and propose the most cost effective options for the developing world.

• **Organized education course** in immunotherapy to be held in Santiago, (together with Angel Oñate, Universidad de Concepción, Chilean Society for Immunology). Area of need and free of ZIKA which was raised as an issue by several potential teachers of the course. Proposed dates originally planned for February 2017 but will be postponed until budget arrangements in place.

• **Have established contacts** and potential collaborators so far have included the American Cancer Society, Cancer Research Institute (CRI), Cancer Research UK (CRUK), and Society for Immunotherapy of Cancer (SITC) (**Lisa Butterfield of SITC on Committee**).
ITH Committee Activities

- Joint grant (50/50 split for 100,000Euro x 3 years) (in progress for October 1\textsuperscript{st})

- Applying for a joint ICSU (International Council for Science) grant with Michael Spedding (Secretary General IUPHAR). International Union of Basic and Clinical Pharmacology is a good partner with more $1million of other grants (i.e. Wellcome) and have established a highly successful website [http://www.guidetopharmacology.org](http://www.guidetopharmacology.org). ICSU is “a voluntary, non-profit association representing the interests of scientists in pharmacology-related fields facilitate Better Medicines through Global Education and Research around the world”.

- 1) simple validated immunological protocols around drug targets, which can be performed in labs without major facilities. IUIS and IUPHAR can meet this gap.
- 2) supply scientific education to the developing (and developed) world via a publicly available web sites backed up by expert subcommittees. Would partly involve their already established [http://www.guidetopharmacology.org](http://www.guidetopharmacology.org) but no restrictions on the use of information for IUIS and affiliate websites. Joint activities.
- 3) special emphasis on natural products which may be more affordable to the developing world.